Market Overview

KKR to Acquire Minority Stake in Gland Pharma for $200M


Gland Pharma Limited today
announced an agreement under which KKR, a leading global investment
firm, will acquire a minority stake in the Company for approximately
US$200 million, including KKR's acquisition of the entire stake held by
Evolvence India Life Sciences Fund (”EILSF”), an existing private equity
investor in Gland Pharma.

Established in 1978 and based in Hyderabad, Gland Pharma develops and
manufactures generic injectables primarily for the US market, and also
for India and other semi-regulated markets. In 2003, Gland Pharma was
the first company in India to get US Food and Drug Administration (FDA)
approval for pharmaceutical liquid injectable products. Gland

See full press release

Posted-In: News Guidance Financing Contracts Management M&A Global


Related Articles (KKR)

View Comments and Join the Discussion!

Partner Center